{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yagi H"],"funding":["Massachusetts Lions Eye Research Fund","NICHD NIH HHS","NEI NIH HHS","Svenska Forskningsrådet Formas","The Wallenberg Clinical Scholars","Boston Children's Hospital","NHLBI NIH HHS","Government grants under the ALF agreement","Kowa Company","National Institutes of Health","NIH HHS","Boston Children’s Hospital"],"pagination":["903-917"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11564262"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(4)"],"pubmed_abstract":["Pathological neovascularization in retinopathy of prematurity (ROP) can cause visual impairment in preterm infants. Current ROP treatments which are not preventative and only address late neovascular ROP, are costly and can lead to severe complications. We showed that topical 0.1% dexamethasone eye drops administered prior to peak neovessel formation prevented neovascularization in five extremely preterm infants at high risk for ROP and suppressed neovascularization by 30% in mouse oxygen-induced retinopathy (OIR) modeling ROP. In contrast, in OIR, topical dexamethasone treatment before any neovessel formation had limited efficacy in preventing later neovascularization, while treatment after peak neovessel formation had a non-statistically significant trend to exacerbating disease. Optimal"],"journal":["Angiogenesis"],"pubmed_title":["Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity."],"pmcid":["PMC11564262"],"funding_grant_id":["OFD/BTREC/CTREC Faculty Career Development Grant 97906","DNR# #2020-01092","P50 HD105351","R01 EY032492","ALFGBG-717971","R01 EY017017","R01EY017017","R01 HL149302","R01HL126901","R01 HL126901","IDDRC (1U54HD090255)","R01 EY030904","U54 HD090255"],"pubmed_authors":["Kasai T","Negishi K","Neilsen K","Wang C","Joyal JS","Petrishka-Lozenska M","Lee J","Fu Z","Cagnone G","Tomita Y","Aikawa M","Smith LEH","Boeck M","Hellstrom A","Yagi H","Singh SA","Lundgren P"],"additional_accession":[]},"is_claimable":false,"name":"Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity.","description":"Pathological neovascularization in retinopathy of prematurity (ROP) can cause visual impairment in preterm infants. Current ROP treatments which are not preventative and only address late neovascular ROP, are costly and can lead to severe complications. We showed that topical 0.1% dexamethasone eye drops administered prior to peak neovessel formation prevented neovascularization in five extremely preterm infants at high risk for ROP and suppressed neovascularization by 30% in mouse oxygen-induced retinopathy (OIR) modeling ROP. In contrast, in OIR, topical dexamethasone treatment before any neovessel formation had limited efficacy in preventing later neovascularization, while treatment after peak neovessel formation had a non-statistically significant trend to exacerbating disease. Optimal","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-02T03:36:02.845Z","creation":"2025-04-04T12:01:13.642Z"},"accession":"S-EPMC11564262","cross_references":{"pubmed":["39287727"],"doi":["10.1007/s10456-024-09948-2"]}}